Anti-&#x03B1;-enolase is a prognostic marker in postoperative lung cancer patients

Kuan-Chung Hsiao; Neng-Yao Shih; Pei-Yi Chu; Yi-Mei Hung; Jia-Yi Liao; Shao-Wen Chou; Yi-Yuan Yang; Gee-Chen Chang; Ko-Jiunn Liu

doi:10.18632/oncotarget.5316

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Anti-α-enolase is a prognostic marker in postoperative lung cancer patients

Kuan-Chung Hsiao, Neng-Yao Shih, Pei-Yi Chu, Yi-Mei Hung, Jia-Yi Liao, Shao-Wen Chou, Yi-Yuan Yang, Gee-Chen Chang _ and Ko-Jiunn Liu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:35073-35086. https://doi.org/10.18632/oncotarget.5316

Metrics: PDF 1275 views | HTML 2170 views | ?

Abstract

Kuan-Chung Hsiao1,2, Neng-Yao Shih2, Pei-Yi Chu3,4, Yi-Mei Hung2, Jia-Yi Liao2, Shao-Wen Chou2, Yi-Yuan Yang5, Gee-Chen Chang6,7,8,9,*, Ko-Jiunn Liu1,2,5,*

1Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan

2National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

3School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan

4Department of Pathology, Show Chwan Memorial Hospital, Changhua City, Taiwan

5School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, Taiwan

6Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

7Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

8Institute of Biomedical Sciences, National Chung-Hsing University, Taichung, Taiwan

9School of Medicine, China Medical University, Taichung, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Gee-Chen Chang, e-mail: [email protected]

Ko-Jiunn Liu, e-mail: [email protected]

Keywords: lung cancer, ENO1

Received: April 24, 2015 Accepted: September 15, 2015 Published: September 26, 2015

ABSTRACT

Our previous studies suggest that antibodies against ENO1 (anti-ENO1 Ab) have a protective role in patients with non-small cell lung carcinoma. In this study, we evaluated the prognostic value of anti-ENO1 Ab levels in non-small cell lung carcinoma patients undergoing surgery. Circulating levels of anti-ENO1 Ab were assessed in 85 non-small cell lung carcinoma patients before and after surgery, and were correlated with clinical outcome. After surgery, patients with a higher increase of anti-ENO1 Ab had a lower hazard ratio and a better progression-free survival. Using animal models, we demonstrated that tumor cells reduce the circulating levels of anti-ENO1 Ab through physical absorption and neutralization of anti-ENO1 Ab with surface-expressed and secreted ENO1, respectively. Mice transplanted with ENO1-overexpressing tumors generated ENO1-specific regulatory T cells to suppress the production of anti-ENO1 Ab. Our results suggest that the increase of anti-ENO1 Ab may reflect anti-tumor immune responses and serve as a prognostic marker in postoperative lung cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5316

Publication Alerts

Clinical Research Papers:

Anti-α-enolase is a prognostic marker in postoperative lung cancer patients

Abstract